[Interleukin-7, a new immunoadjuvant for the treatment of septic shock]

Med Sci (Paris). 2014 Feb;30(2):160-5. doi: 10.1051/medsci/20143002013. Epub 2014 Feb 24.
[Article in French]

Abstract

Sepsis-induced immunosuppression is a new paradigm in sepsis pathophysiology. This up-to-date review integrates recent facts in the field. It focuses on immune dysfunctions described so far in septic patients (especially regarding T lymphocytes), on the mechanisms sustaining this immune failure, on the monitoring of the pro-/anti-inflammatory balance rapidly changing over time and on new promising therapeutic avenues emerging from those recent findings. Of them, the case of interleukin-7 is more specifically envisaged.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic*
  • Apoptosis
  • CD4 Lymphocyte Count
  • Humans
  • Immunosuppression Therapy
  • Interleukin-7 / physiology
  • Interleukin-7 / therapeutic use*
  • Lymphopenia
  • Receptors, Interleukin-7
  • Recombinant Proteins
  • Shock, Septic / drug therapy*
  • Shock, Septic / immunology
  • T-Lymphocytes / immunology

Substances

  • Adjuvants, Immunologic
  • Interleukin-7
  • Receptors, Interleukin-7
  • Recombinant Proteins